3 completed, 1 active not recruiting, 1 recruiting. 3 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Not applicable | 1 | Active not recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Peripheral Primitive Neuroectodermal Tumor: new trials by email Literature Review of Peripheral Primitive Neuroectodermal Tumor trials Research Report on Peripheral Primitive Neuroectodermal Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors Lutetium Lu 177-Edotreotide, Amino Acid Solution - Somatostatin Receptor Positive, NETs | Phase 1 | Recruiting | ITM Solucin GmbH | 20 | 2025-09-26 | 2026-10-27 |
| Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD FoundationOne Liquid CDx - Ewing Sarcoma, Ewing Sarcoma of Bone | Not applicable | Active not recruiting | Dana-Farber Cancer Institute | 340 | 2018-05-08 | 2026-05-05 |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Vemurafenib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2017-11-08 | 2025-01-27 |
| Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma topotecan hydrochloride, vincristine sulfate, cyclophosphamide - Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 7 | 2008-02-01 | 2014-09-02 |
| Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors trabectedin, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma | Phase 2 | Completed | Children's Oncology Group | 50 | 2008-01-01 | 2018-09-14 |
Neuroectodermal Tumors, Primitive, Peripheral (5) · Sarcoma, Ewing (3) · Central Nervous System Neoplasms (2) · Rhabdomyosarcoma (2) · Ependymoma (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Glioma (1) · Hepatoblastoma (1) · Histiocytosis, Langerhans-Cell (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Neuroblastoma (1) · Neuroendocrine Tumors (1) · Osteosarcoma (1) · Rhabdoid Tumor (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neoplasms, Neuroepithelial (5) · Neuroectodermal Tumors (5) · Neuroectodermal Tumors, Primitive (5) · Neoplasms, Connective and Soft Tissue (4) · Neoplasms, Bone Tissue (3) · Neoplasms, Connective Tissue (3) · Sarcoma (3) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2)
177Lu-octreotide, DOTA(0)-Tyr(3)- (1) · Bevacizumab (1) · Cyclophosphamide (1) · Liquid Biopsy (1) · Topotecan (1) · Trabectedin (1) · Vemurafenib (1) · Vincristine (1) · amino-acid, glucose, and electrolyte solution (1) · trioctyl phosphine oxide (1)
National Cancer Institute (NCI) (2) · Children's Oncology Group (1) · Dana-Farber Cancer Institute (1) · ITM Solucin GmbH (1)
United States (5) · Canada (1) · France (1) · Puerto Rico (1) · Spain (1)
AeRang Kim (1) · David S Shulman, MD (1) · Patrick Leavey, MD (1) · Roman Henkel, PhD (1) · Sylvain Baruchel, MD (1)
PMID 22088484, PMID 31401903, PMID 38873934
U10CA098543 (2), U10CA180886 (1)